The Activin - ActRII - ActRI pathway plays a vital role in cell growth and differentiation, and understanding its mechanism of action is essential.

The Activin - ActRII - ActRI pathway is a key regulatory pathway in muscle growth and has attracted significant attention in the research of muscle - related diseases and weight - loss therapies.

With the widespread use of Semaglutide in weight management, the issue of weight rebound after discontinuation has emerged as a significant challenge.

Semaglutide has been increasingly utilized for chronic weight management in obese or overweight adults due to its remarkable weight - loss effects.

This report outlines the process of monoclonal antibody drug patent research with the investigation of BeiGene patent portfolio related to its tislelizumab monoclonal antibody.

Tislelizumab, referred to as bazeleus, represents a humanized IgG4 monoclonal antibody targeting PD-1.

Keytruda has rapidly ascended to become the top-selling drug in the market, underscoring the significance of monoclonal antibodies in modern medicine.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Based on the characteristics of ADC drugs, we have summarized the process for conducting patent research on ADC drugs.

Currently, 272 ADC drugs have been initiated for clinical trials globally. Excluding the market withdrawal of Belantamab mafodotin (Blenrep®), 14 approved ADC products remain available.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.

Based on the characteristics of siRNA drugs, we have summarized the process for conducting patent research on siRNA drugs.